Clinical course and prognosis of never-smokers with severe alpha-1-antitrypsin deficiency (PiZZ)

Background: Previous studies of non-smoking individuals with severe α1-antitrypsin deficiency (PiZZ) have been sparse and included only a limited number of individuals, mostly identified by respiratory symptoms. The aim of this study was to estimate the prognosis of non-smoking PiZZ individuals and to analyse the most common causes of death by including a large number of individuals who had been identified by other means than respiratory symptoms. Methods: The study included 568 non-smoking PiZZ subjects who were selected from the Swedish National AAT Deficiency Registry and followed up from 1991 to September 2007. Of these, 156 (27%) were identified by respiratory symptoms (respiratory cases) and 412 were identified by extrapulmonary symptoms or screening (non-respiratory cases). Results: 93 subjects (16%) died during the follow-up period. The specific standardised mortality rate (SMR) for the whole study population was 2.32 (95% CI 1.87 to 2.83) with no significant difference between men and women. The SMR was 2.55 (95% CI 1.91 to 2.83) for the respiratory cases and 2.07 (95% CI 1.49 to 2.81) for the non-respiratory cases. Further calculation of SMR for subgroups in the non-respiratory cases showed that the SMR was 0.70 (95% CI 0.14 to 2.04) for individuals identified by family/population screening. Emphysema and liver cirrhosis were the most common causes of death (45% and 28%, respectively). Malignant transformation was found in 38% of the cases with cirrhosis. Conclusion: Non-smoking PiZZ individuals identified by screening do not have an increased mortality risk compared with the Swedish general population.

[1]  C. Larsson.  Natural history and life expectancy in severe alpha1-antitrypsin deficiency, Pi Z. , 2009, Acta medica Scandinavica.

[2]  Jeffrey D. Morton,et al.  Persistent activation of an innate immune response translates respiratory viral infection into chronic lung disease , 2008, Nature Medicine.

[3]  E. Piitulainen,et al.  Respiratory symptoms and lung function in 30-year-old individuals with alpha-1-antitrypsin deficiency. , 2007, Respiratory medicine.

[4]  R. Stockley,et al.  Ongoing research in Europe: Alpha One International Registry (AIR) objectives and development , 2007, European Respiratory Journal.

[5]  M. Schluchter,et al.  Mortality in individuals with severe deficiency of alpha1-antitrypsin: findings from the National Heart, Lung, and Blood Institute Registry. , 2005, Chest.

[6]  A. Dirksen,et al.  American Thoracic Society/European Respiratory Society: Standards in Diagnostik und Therapie bei Patienten mit Alpha-1-Antitrypsin-Mangel , 2005 .

[7]  A. Dirksen,et al.  Standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency: Executive summary , 2003 .

[8]  E. Piitulainen,et al.  Effect of age and occupational exposure to airway irritants on lung function in non-smoking individuals with alpha 1-antitrypsin deficiency (PiZZ). , 1997, Thorax.

[9]  S. Eriksson,et al.  Risk of hepatobiliary disease in adults with severe α1-antitrypsin deficiency (PiZZ): is chronic viral hepatitis B or C an additional risk factor for cirrhosis and hepatocellular carcinoma? , 1996, European journal of gastroenterology & hepatology.

[10]  A. Dirksen,et al.  Survival of patients with severe alpha 1-antitrypsin deficiency with special reference to non-index cases. , 1994, Thorax.

[11]  E. Silverman,et al.  Variability of pulmonary function in alpha-1-antitrypsin deficiency: clinical correlates. , 1989, Annals of internal medicine.

[12]  R. Crystal,et al.  Molecular basis of alpha-1-antitrypsin deficiency. , 1988, The American journal of medicine.

[13]  D. Cox,et al.  DNA restriction-site polymorphisms associated with the alpha 1-antitrypsin gene. , 1987, American journal of human genetics.

[14]  J. Carlson,et al.  Risk of cirrhosis and primary liver cancer in alpha 1-antitrypsin deficiency. , 1986, The New England journal of medicine.

[15]  A. Miller,et al.  Standardized lung function testing. , 1984, Bulletin europeen de physiopathologie respiratoire.

[16]  T Sveger,et al.  Liver disease in alpha1-antitrypsin deficiency detected by screening of 200,000 infants. , 1976, The New England journal of medicine.

[17]  P. Vanhoutte.  Endothelium-derived relaxing factors , 1995, European Journal of Medicinal Chemistry.

[18]  Standardized lung function testing. Official statement of the European Respiratory Society. , 1993, The European respiratory journal. Supplement.

[19]  M. Tobin,et al.  Alpha 1 antitrypsin deficiency: the clinical and physiological features of pulmonary emphysema in subjects homozygous for Pi type Z. A survey by the British Thoracic Association. , 1983, British journal of diseases of the chest.

[20]  M. Tobin,et al.  Alpha 1 antitrypsin deficiency: the clinical and physiological features of pulmonary emphysema in subjects homozygous for Pi type Z. A survey by the British Thoracic Association. , 1983, British journal of diseases of the chest.

[21]  J. Jeppsson,et al.  Typing of genetic variants of alpha 1-antitrypsin by electrofocusing. , 1982, Clinical chemistry.

[22]  L. F. Black,et al.  alpha1-Antitrypsin deficiency in nonsmokers. , 1978, The American review of respiratory disease.

[23]  S. Eriksson.  Studies in alpha 1-antitrypsin deficiency. , 1965, Acta medica Scandinavica. Supplementum.